TABLE 1.
Baseline demographics and disease characteristics (ITT)
| Pooled SINUS‐24 and SINUS‐52 | |||
|---|---|---|---|
| Placebo (n = 286) |
Dupilumab 300 mg q2w (n = 438) |
Overall (n = 724) | |
| Age, mean (SD), years | 51.28 (12.90) | 51.47 (12.79) | 51.39 (12.83) |
| Male sex, n (%) | 165 (57.7) | 272 (62.1) | 437 (60.4) |
| NC score, mean (SD) [range 0–3] | 2.41 (0.54) | 2.39 (0.60) | 2.40 (0.58) |
| TSS, mean (SD) [range 0–9] | 7.18 (1.39) | 7.14 (1.45) | 7.16 (1.43) |
| VAS for overall rhinosinusitis, mean (SD) [range 0–10] | 7.97 (2.14) | 7.82 (2.02) | 7.88 (2.07) |
| SNOT‐22 total score, mean (SD) [range 0–110] a | 52.27 (21.11) | 50.05 (20.33) | 50.94 (20.66) |
| Nasal domain, mean (SD) [range 0–5] a | 3.12 (0.83) | 3.05 (0.81) | 3.08 (0.82) |
| Ear/facial domain, mean (SD) [range 0–5] a | 1.44 (1.23) | 1.33 (1.09) | 1.37 (1.15) |
| Sleep domain, mean (SD) [range 0–5] a | 2.39 (1.41) | 2.29 (1.40) | 2.33 (1.40) |
| Function domain, mean (SD) [range 0–5] a | 2.22 (1.39) | 2.07 (1.39) | 2.13 (1.39) |
| Emotion domain, mean (SD) [range 0–5] a | 1.79 (1.34) | 1.65 (1.36) | 1.71 (1.35) |
| EQ‐VAS (health status), mean (SD) [range 0–100] b | 64.9 (20.6) | 65.8 (20.3) | 65.4 (20.4) |
Abbreviations: EQ‐VAS, EuroQoL‐visual analog scale; HRQoL, health‐related quality of life; ITT, intention to treat; NC, nasal congestion; q2w, every 2 weeks; SD, standard deviation; SNOT‐22, 22‐item sino‐nasal outcome test; TSS, total symptom score; VAS, visual analog scale.
a
Higher scores represent worse HRQoL.
b
Higher scores indicate better health status.